Malin delivered strong value realisation in 2024 through major divestments, boosting cash reserves and intrinsic equity value per share, and announced a €150 million capital return to shareholders, while maintaining a disciplined focus on its remaining life sciences investments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.